Aetna only covers Wegovy for indications approved by the Food and Drug Administration (FDA)
The key results: 13.6% average weight loss with oral semaglutide, compared to 2.2% with placebo 76.3% of people on the pill achieved at least 5% weight loss, compared to 31.3% on placebo 55.6% achieved at least 10% weight loss Around 30% achieved 20% or more weight loss Theres an important distinction in how these results are reported
However, they have garnered never-before-seen levels of medical, media and business attention over the last few months, following the announcement of recent successful clinical trial results demonstrating the more widespread health benefits of certain GLP-1RAs
Insomnia was confirmed by monitoring sleep disturbances and alterations in neurotransmitter levels using high-performance liquid chromatography (HPLC)
Neglect any one and you could lose 20-50% of effective peptide content before the vial is empty
The same active molecule: Compounded semaglutide delivers the identical GLP-1 receptor agonist as brand-name Wegovy, prepared by U.S.-licensed pharmacies under federal compounding regulations